• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trametinib-Induced Remission of an -Mutated Langerhans Cell Histiocytosis.

作者信息

Papapanagiotou Matina, Griewank Klaus G, Hillen Uwe, Schimming Tobias T, Moeller Lars C, Führer Dagmar, Zimmer Lisa, Roesch Alexander, Sucker Antje, Schadendorf Dirk, Livingstone Elisabeth, Schilling Bastian

机构信息

Matina Papapanagiotou, Klaus G. Griewank, Uwe Hillen, Tobias T. Schimming, Lars C. Moeller, Dagmar Führer, Lisa Zimmer, Alexander Roesch, Antje Sucker, Dirk Schadendorf, Elisabeth Livingstone, and Bastian Schilling, University Hospital, University of Duisburg-Essen, Essen; and Bastian Schilling, University Hospital Würzburg, Würzburg, Germany.

出版信息

JCO Precis Oncol. 2017 Nov;1:1-5. doi: 10.1200/PO.16.00070.

DOI:10.1200/PO.16.00070
PMID:35172489
Abstract
摘要

相似文献

1
Trametinib-Induced Remission of an -Mutated Langerhans Cell Histiocytosis.曲美替尼诱导的BRAF V600E突变型朗格汉斯细胞组织细胞增生症缓解
JCO Precis Oncol. 2017 Nov;1:1-5. doi: 10.1200/PO.16.00070.
2
Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.朗格汉斯细胞组织细胞增生症伴 BRAF p.N486_P490del 或 MAP2K1 p.K57_G61del，用 MEK 抑制剂曲美替尼治疗。
Pediatr Blood Cancer. 2020 Dec;67(12):e28712. doi: 10.1002/pbc.28712. Epub 2020 Sep 29.
3
Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib.基于计算机的研究：失活/激活突变对曲美替尼抑制 MEK1 的影响。
Int J Mol Sci. 2020 Mar 21;21(6):2167. doi: 10.3390/ijms21062167.
4
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.表皮生长因子受体（EGFR）和丝裂原活化蛋白激酶1/2（MEK1/2）抑制剂在胆管癌治疗中的临床前活性
Oncotarget. 2016 Aug 9;7(32):52354-52363. doi: 10.18632/oncotarget.10587.
5
Improvement in Pituitary Imaging After Targeted Therapy in Three Children with -Mutated Langerhans Cell Histiocytosis with Pituitary Involvement.3例垂体受累的BRAF突变朗格汉斯细胞组织细胞增生症患儿经靶向治疗后垂体影像学改善。
Onco Targets Ther. 2020 Dec 1;13:12357-12363. doi: 10.2147/OTT.S279093. eCollection 2020.
6
Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation.MEK1/2 与曲美替尼相互作用的分子机制研究：对接和分子动力学模拟。
Interdiscip Sci. 2019 Mar;11(1):115-124. doi: 10.1007/s12539-018-0305-4. Epub 2018 Nov 21.
7
Swelling of bilateral parotid glands: An unusual symptom of multisystem Langerhans cell histiocytosis.双侧腮腺肿大：多系统朗格汉斯细胞组织细胞增多症的一种不寻常症状。
SAGE Open Med Case Rep. 2014 Apr 7;2:2050313X14531220. doi: 10.1177/2050313X14531220. eCollection 2014.
8
Congenital Langerhans cell histiocytosis presenting in a 27-week-gestation neonate.一名孕27周新生儿患先天性朗格汉斯细胞组织细胞增多症。
Pediatr Dermatol. 2018 Mar;35(2):e140-e141. doi: 10.1111/pde.13416. Epub 2018 Feb 13.
9
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.患者朗格汉斯细胞组织细胞增生症中一种新型 MAP2K1 突变相关的临床耐药性。
Pediatr Blood Cancer. 2018 Sep;65(9):e27237. doi: 10.1002/pbc.27237. Epub 2018 May 16.
10
Genomic Alterations in Langerhans Cell Histiocytosis.朗格汉斯细胞组织细胞增多症中的基因组改变。
Hematol Oncol Clin North Am. 2015 Oct;29(5):839-51. doi: 10.1016/j.hoc.2015.06.004.

引用本文的文献

1
Langerhans Cell Histiocytosis With Mutation Successfully Treated With Trametinib.携带突变的朗格汉斯细胞组织细胞增多症经曲美替尼成功治疗
EJHaem. 2025 May 27;6(3):e70067. doi: 10.1002/jha2.70067. eCollection 2025 Jun.
2
Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease.成人朗格汉斯细胞组织细胞增生症和 Erdheim-Chester 病的靶向治疗现状。
Target Oncol. 2024 Sep;19(5):691-703. doi: 10.1007/s11523-024-01080-x. Epub 2024 Jul 11.
3
Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis.
双侧全葡萄膜炎与使用曲美替尼治疗朗格汉斯细胞组织细胞增多症的关联。
Am J Transl Res. 2022 Dec 15;14(12):8768-8772. eCollection 2022.
4
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症中的信号通路、微环境和靶向治疗。
Cell Commun Signal. 2022 Dec 19;20(1):195. doi: 10.1186/s12964-022-00917-0.
5
Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis.一名难治性混合组织细胞增多症患者在更换MEK抑制剂后出现显著反应。
J Hematol. 2022 Oct;11(5):185-189. doi: 10.14740/jh1030. Epub 2022 Oct 31.
6
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.国际专家共识建议：成人朗格汉斯细胞组织细胞增生症的诊断与治疗。
Blood. 2022 Apr 28;139(17):2601-2621. doi: 10.1182/blood.2021014343.
7
Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.儿童 MAP2K1 突变朗格汉斯细胞组织细胞增生症的临床研究。
J Cancer Res Clin Oncol. 2022 Sep;148(9):2517-2527. doi: 10.1007/s00432-021-03810-4. Epub 2021 Sep 30.
8
Leveraging Systematic Functional Analysis to Benchmark an Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.利用系统功能分析对癌症中区分驱动和乘客 MEK 突变体的 框架进行基准测试。
Cancer Res. 2020 Oct 1;80(19):4233-4243. doi: 10.1158/0008-5472.CAN-20-0865. Epub 2020 Jul 8.
9
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.存在 MAP2K1 框内缺失的黑色素瘤：一种与 BRAF、NRAS 和 NF1 突变相互排斥的独特的皮肤黑色素瘤分子亚型。
Mod Pathol. 2020 Dec;33(12):2397-2406. doi: 10.1038/s41379-020-0581-5. Epub 2020 Jun 1.
10
A case of class 3 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors.1例3级突变型转移性结直肠癌患者，其肿瘤标志物对MEK和ERK抑制剂反应不持久。
J Gastrointest Oncol. 2019 Dec;10(6):1140-1143. doi: 10.21037/jgo.2019.08.02.